Zantac is defective by design

For decades, millions of people relied on Zantac and its generic counterpart, ranitidine. In addition to being sold as an over the counter alternative to prescription drugs for acid-reflux, ranitidine was used to treat gastroesophageal reflux disease (GERD), ulcers, mastocytosis, esophagitis, and various other chronic diseases.

At the start of April 2020, the FDA revealed that Zantac was both defective and dangerous for human use, issuing the immediate market recall of all ranitidine drugs. In 2019, routine lab testing showed that Zantac products contained traces of a probable human carcinogen, N-Nitrosodimethylamine (NDMA).

While low levels of NDMA exposure increase human risk for cancer, there is now evidence that the NDMA in Zantac can also rise overtime, potentially exceeding the acceptable daily intake limit under normal storage conditions and when broken down in the human body. This defect was originally only linked to batches of ranitidine that were manufactured for use between September 2019 and June 2021. However, the FDA has advised all consumers of ranitidine products to discontinue current use and dispose of remaining ranitidine products.

If you have experienced any changes in health after taking Zantac products, contact your physician and call Reich & Binstock. We can help you file a claim and provide information about your right to recover damages for pain and suffering.